CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 238
Phase 3
Completed
- Conditions
- Melanoma
- Registration Number
- JPRN-jRCT2080222893
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects less than 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is at least 18 years of age.
Completely removed melanoma by surgery performed within 12 weeks of randomization.
Stage 3b/C or Stage 4 before complete resection.
No previous anti-cancer treatment.
Exclusion Criteria
Ocular or uveal melanoma.
History of carcinomatosis meningitis.
History of auto-immune disease.
Treatment directed against the resected melanoma that is administrated after the surgery.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence -free-survival.
- Secondary Outcome Measures
Name Time Method Overall survival.